Colcrys
Colcrys
- In many regulated markets Colcrys (colchicine) is classified as prescription-only, but some pharmacies and online vendors may sell colchicine without a prescription or receipt; availability and delivery to the United Kingdom vary by supplier—be aware that local laws and pharmacy policies may restrict or prohibit non-prescription sales.
- Colcrys is used to treat acute gout flares, to prevent recurrent gout attacks (prophylaxis), for Familial Mediterranean Fever (FMF) and, at low doses, for certain cardiovascular risk reduction strategies; colchicine works by binding to tubulin and inhibiting microtubule polymerisation, reducing neutrophil activity and the inflammatory response.
- Usual dosages: acute gout — 1.2 mg at onset then 0.6 mg one hour later (maximum 1.8 mg in one hour) or alternative label regimens up to labelled limits; prophylaxis — 0.6 mg once or twice daily; FMF — typically 1.2–2.4 mg/day in divided doses in adults (children ≥4 years often start 0.6–1.2 mg/day and are titrated); cardiovascular studies use ~0.5–0.6 mg once daily; adjust or avoid in renal/hepatic impairment and the elderly.
- Administration is oral — 0.6 mg film-coated tablets (Colcrys, Lodoco), capsules (Mitigare) or an oral solution (Gloperba 0.6 mg/5 mL).
- Onset: symptomatic relief is often noticed within 12–24 hours after an early dose for gout attacks, though some patients may report improvement within a few hours when treatment is started promptly.
- Duration of action: the anti-inflammatory effect from a single dose commonly persists for up to 24 hours; for prophylaxis and FMF the effect is maintained with once- or twice-daily dosing.
- Alcohol warning: avoid excessive alcohol while taking colchicine — alcohol can worsen gout and liver function and may increase gastrointestinal and hepatic side effects; limit intake and consult a clinician if you have liver disease.
- The most common side effects are gastrointestinal — diarrhoea, nausea, vomiting and abdominal pain; other effects can include fatigue, myalgia, headache and, rarely, reversible alopecia or bone marrow suppression in severe toxicity.
- Would you like to try “colcrys” without a prescription?
Basic Colcrys Information
- INN (International Nonproprietary Name): Colchicine.
- Brand Names Available In United Kingdom: Marketed as colchicine (generic) with similar dosage forms available; US brands include Colcrys, Gloperba, Mitigare and Lodoco but UK prescribing commonly uses generics.
- ATC Code: M04AC01.
- Forms & Dosages: Tablet 0.6 mg; Capsule 0.6 mg; Oral solution 0.6 mg/5 mL (example brands: Colcrys, Mitigare, Gloperba).
- Manufacturers In United Kingdom: Multiple generics supplied by EU/global manufacturers (examples in the wider market include Teva, Zentiva, Hikma, Prasco; local procurement varies).
- Registration Status In United Kingdom: Marketed as colchicine (generic) under national licences and EMA monographs; check MHRA for current licensing details.
- OTC / Rx Classification: Prescription only / Rx.
Latest Research Highlights
What Does Recent UK and EU Research Say About Colchicine?
Colchicine research in the UK and EU (2022–2025) emphasises modest benefit for acute gout control, consistent prophylactic efficacy for gout flares and FMF, and emerging low‑dose cardiovascular inflammation signals.
| Study | Population | Intervention | Primary Outcome | Safety Signal |
|---|---|---|---|---|
| Systematic Reviews (2022–2024) | Adults with gout | Colchicine 0.6 mg once or twice daily; acute single regimens | Reduced flare recurrence with prophylaxis; modest effect on acute pain when given promptly | Gastrointestinal adverse events most common; discontinuation due to diarrhoea. |
| NHS-Linked Cohort Analyses (UK Audit) | Primary care patients prescribed colchicine | Prophylactic 0.6 mg OD/BID; counselling vs no counselling | Lower flare rates and better adherence when pharmacist counselling included | GI events leading to stopping treatment; drug interactions with CYP3A4/P‑gp inhibitors flagged. |
| FMF Registry Studies (EU, 2022–2025) | Paediatric and adult FMF patients | Chronic colchicine 1.2–2.4 mg/day | Reduced attack frequency and lower amyloidosis risk | Generally well tolerated at low doses; GI events remain common; rare haematological events reported. |
| Pharmacovigilance Reports (MHRA / EudraVigilance) | Post‑marketing cases | Colchicine with interacting drugs | Signal detection for severe toxicity with concomitant strong CYP3A4/P‑gp inhibitors | Serious toxicity including myopathy, neutropenia and fatal outcomes in severe renal/hepatic impairment. |
Key Data Highlights.
- Most marketed forms are 0.6 mg tablets or capsules and oral solution such as Gloperba, ATC M04AC01.
- Maximum acute single‑dose regimens: 1.8 mg administered within 1 hour is used in acute gout protocols.
- Chronic FMF dosing commonly ranges 1.2–2.4 mg/day in divided doses.
- Safety messages repeatedly stress interactions with strong CYP3A4 and P‑gp inhibitors as a cause of serious toxicity.
Clinical Effectiveness In The UK
Will Colchicine Help My Gout Or FMF?
- NHS Outcome Measures: Reduction in flare frequency, time to pain relief, adherence to prophylaxis, incidence of adverse events, and hospital admissions for complications.
- Primary Care Performance Indicators: Prompt prescribing within 24 hours of onset for gout, pharmacist counselling rates, and electronic prescription follow‑up completion.
- Specialist Clinic Measures: Attack frequency and amyloidosis incidence for FMF registries; dose titration success rates.
Short Definitions For Common Terms.
- NNT: Number needed to treat to prevent one event.
- HR: Hazard ratio; relative risk over time in cohort studies.
| Measure | Typical Result |
|---|---|
| Pain Reduction For Acute Gout | Patient‑reported reduction within 24–48 hours when started promptly. |
| Flare Prevention With Prophylaxis | Lower recurrence rates with 0.6 mg OD/BID; improved adherence with pharmacist counselling. |
Clinical Notes.
Colchicine is effective for aborting gout flares when administered promptly, and for reducing flare frequency as prophylaxis.
In FMF, paediatric and adult registries in Europe confirm that colchicine lowers attack frequency and reduces the risk of amyloidosis when titrated appropriately.
Effectiveness is tempered by tolerability; diarrhoea and vomiting frequently limit adherence in routine NHS practice.
MHRA case series document rare but serious myelosuppression and neuromyopathy, particularly in those with renal impairment or interacting medicines.
In primary care audits, many patients reported meaningful pain relief within 48 hours if colchicine was given early; some GPs still prefer NSAIDs first‑line due to quicker symptomatic relief in suitable patients.
Indications And Expanded Uses
What Is Colchicine Licensed For And Where Is It Used Off‑Label?
| MHRA‑Approved Indications | Common Off‑Label Uses |
|---|---|
| Acute gout attacks; gout prophylaxis; Familial Mediterranean Fever (FMF). | Low‑dose use in selected cardiovascular inflammation studies; specialist use for pericarditis in rheumatology; occasional dermatology trials. |
Practical Points.
Colchicine is prescription‑only and widely used for acute gout and for chronic FMF therapy.
Off‑label cardiology use (low‑dose colchicine for secondary prevention) occurs in specialist settings and often requires local formulary approval in NHS trusts.
Private clinics conducting off‑label prescribing follow MHRA guidance to obtain informed consent and monitor for interactions with statins, macrolides and antifungals.
Short Definitions.
- On‑Label: Use covered by the product licence.
- Off‑Label: Use outside the licence but clinically supported and overseen by specialists.
- Prophylaxis: Long‑term low‑dose therapy to prevent attacks.
- Chronic Use: Continued administration for conditions such as FMF with periodic monitoring.
Composition And Brand Landscape
Which Forms And Brands Are Available In The UK Market?
| Form | Strength | Example Brand/Supplier |
|---|---|---|
| Tablet | 0.6 mg | Generic colchicine (market examples include Colcrys in wider markets) |
| Capsule | 0.6 mg | Mitigare (example in some markets); generics supplied by EU manufacturers |
| Oral Solution | 0.6 mg/5 mL | Gloperba (oral solution) |
Packaging And Sourcing Notes.
- The active ingredient is colchicine (INN).
- Most common strength in the UK is 0.6 mg; 1 mg strengths are not the standard in current marketed packs.
- NHS procurement favours cost‑effective generics from suppliers such as Teva, Zentiva and Hikma.
- Community pharmacies (Boots, LloydsPharmacy and online providers) typically stock generic 0.6 mg tablets; oral solution is available for patients with swallowing difficulties.
Contraindications And Special Precautions
Who Should Not Take Colchicine And When Should You Be Careful?
Absolute Contraindications.
- Hypersensitivity to colchicine.
- Severe renal or hepatic impairment, particularly when combined with strong CYP3A4 or P‑gp inhibitors.
- Concomitant use with strong CYP3A4 or P‑gp inhibitors in the presence of renal/hepatic dysfunction due to risk of fatal toxicity.
Relative Contraindications / Cautions.
- Elderly or frail patients who are more susceptible to toxicity.
- Patients with severe gastrointestinal disease where diarrhoea would be problematic.
- Significant cardiac or haematological disorders; moderate renal or hepatic impairment requires dose adjustment and monitoring.
- Pregnancy and breastfeeding require specialist advice and a documented risk‑benefit discussion in antenatal care.
Practical Decision Flow For Renal Or Hepatic Impairment.
- If severe renal failure or dialysis: avoid colchicine.
- If moderate impairment: reduce dose and monitor blood counts and symptoms.
- Check for interacting drugs (strong CYP3A4/P‑gp inhibitors) before prescribing or dispensing.
Reporting.
Report suspected adverse reactions to the MHRA Yellow Card scheme.
Dosage Guidelines
How Should Colchicine Be Dosed In Different Situations?
| Indication | Adult Dose | Paediatric Notes |
|---|---|---|
| Acute Gout | 1.2 mg at onset, then 0.6 mg 1 hour later (max 1.8 mg in 1 hr); alternate regimens 0.6 mg every 12–24 hrs. | Not approved for gout in children. |
| Gout Prophylaxis | 0.6 mg once or twice daily. | Not approved for prophylaxis in children. |
| FMF | 1.2–2.4 mg/day in one or two divided doses; titrate to response. | For children ≥4 years start 0.6–1.2 mg/day and titrate. |
Special Population Algorithms.
- Elderly: start at lower doses and monitor closely for GI effects and myopathy.
- Moderate renal or hepatic impairment: reduce dose; avoid if severe impairment or dialysis.
- Avoid co‑administration with strong CYP3A4/P‑gp inhibitors unless specialist advice obtained.
- Pharmacists should verify renal function and concurrent medicines before dispensing.
Interactions Overview
Which Drugs Increase The Risk Of Colchicine Toxicity?
| Major Interacting Drugs | Effect / Risk |
|---|---|
| Clarithromycin, Itraconazole, Ketoconazole | Strong CYP3A4 inhibitors increase colchicine levels and risk of severe toxicity. |
| Cobicistat, Ritonavir and some HIV Protease Inhibitors | Strong CYP3A4 and P‑gp inhibition; associated with fatal outcomes in presence of renal/hepatic impairment. |
| Verapamil, Diltiazem | P‑gp/CYP3A4 interactions warrant dose review or avoidance in compromised patients. |
| Statins and Fibrates | Increased risk of myopathy and neuromuscular toxicity when combined with colchicine. |
Minor Interactions And Practical Advice.
- Macrolide antibiotics have been repeatedly implicated in Yellow Card reports; consider temporary suspension or close monitoring.
- Alcohol can worsen hepatic risk; advise moderation in patients with liver disease.
- Check OTC medicines and herbal remedies (eg St John’s wort may alter CYP3A4 activity) as part of the medication review.
- Report suspected interactions and adverse events via the MHRA Yellow Card.
Cultural Perceptions And Patient Habits
What Do Patients Say About Colchicine In The UK?
- Patient forums and NHS feedback show high trust in pharmacist advice and NHS 111 guidance for medication queries.
- Main concerns voiced include diarrhoea, vomiting and worry about long‑term toxicity.
- Many patients prefer in‑person pharmacist counselling at Boots or LloydsPharmacy for immediate questions about dosing and interactions.
- Some GPs take a conservative approach and favour NSAIDs before prescribing colchicine for acute gout, particularly in patients with renal disease.
- Electronic prescriptions and the NHS App increase patient confidence by providing medication leaflets and records.
Patient Quote Themes From Forums.
- “I felt better after a day or two when it was started quickly, but diarrhoea made me stop.”
- “My pharmacist checked my statin and warned about muscle pain—very helpful.”
Availability And Pricing Patterns
How Easily Can Patients Get Colchicine And What Does It Cost?
Colchicine is prescription‑only and is commonly available in community pharmacies such as Boots, LloydsPharmacy and via reputable online pharmacies.
NHS prescription charging varies by devolved nation; England uses the NHS prescription charge system while prescriptions are free in Scotland, Wales and Northern Ireland for most patients subject to local exemptions.
Private purchase costs depend on brand vs generic choice and dispensing fees; pharmacies often stock the lowest‑cost generic aligned with NHS procurement.
Electronic Prescription Service (EPS) streamlines repeat prescriptions and collection from nominated pharmacies.
In our online pharmacy, colcrys is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.
Comparable Medicines And Preferences
What Are The Alternatives For Acute Gout And When Is Colchicine Favoured?
| Medicine | Pros | Cons |
|---|---|---|
| Colchicine | Useful where NSAIDs are contraindicated; effective if started early; suitable for prophylaxis. | GI side effects common; interactions with CYP3A4/P‑gp; dose limits apply. |
| NSAIDs (Naproxen, Indomethacin) | Rapid analgesic effect for many patients. | Contraindicated in peptic ulcer disease and significant CKD; CV risk considerations. |
| Corticosteroids | Effective for severe or polyarticular flares; suitable when NSAIDs contraindicated. | Metabolic and other systemic effects with repeated use. |
For long‑term urate lowering, allopurinol or febuxostat are the appropriate choices rather than colchicine.
Choice in NHS practice depends on comorbidities, interactions and patient preference, and pharmacists provide a pros and cons checklist at dispensing.
Frequently Asked Questions
Q: How quickly will colchicine work for a gout attack?
A: Many patients report meaningful pain reduction within 24–48 hours if colchicine is taken early in the attack, though anti‑inflammatory effects begin sooner and GI side effects can appear first.
Q: Can I take colchicine with my statin?
A: Caution is advised because statins increase the risk of myopathy when combined with colchicine; discuss with your prescriber or pharmacist before taking both.
Q: Is colchicine safe long term?
A: Low‑dose long‑term use is standard for FMF and prophylaxis, but it requires periodic monitoring of renal and hepatic function and blood counts.
Q: What if I miss a dose?
A: Take the missed dose when you remember unless it is close to the next scheduled dose; do not double up.
Definitions.
- Prophylaxis: Ongoing low‑dose treatment to reduce attack frequency.
- CYP3A4 Inhibitor: A drug that reduces metabolism of colchicine and can raise its levels.
- P‑gp: P‑glycoprotein, a transporter that affects colchicine clearance; inhibitors increase colchicine exposure.
Guidelines For Proper Use (Pharmacist Counselling Style)
What Should Pharmacists Tell Patients When Dispensing Colchicine?
- Confirm the indication and exact dose, for example acute gout regimen or FMF maintenance dose.
- Review renal and hepatic function and the full medication list for CYP3A4 or P‑gp inhibitors.
- Warn patients that diarrhoea and nausea are common and advise when to stop and seek help (severe diarrhoea, muscle weakness, unusual bruising).
- Explain missed‑dose guidance and management of accidental overdose—seek immediate medical attention for suspected overdose.
- Advise on storage at 20–25°C and to keep the medicine in its original packaging away from moisture.
- Use the NHS App or patient portal to send electronic patient information leaflets and schedule monitoring for long‑term users.
- Report adverse events via the MHRA Yellow Card and liaise with the prescriber via EPS if dose changes are needed.
- Signpost support groups for FMF and provide written or digital resources such as NHS.uk leaflets.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 5–7 days |
| Manchester | North West England | 5–7 days |
| Birmingham | West Midlands | 5–7 days |
| Glasgow | Scotland | 5–7 days |
| Leeds | West Yorkshire | 5–7 days |
| Edinburgh | Scotland | 5–7 days |
| Bristol | South West England | 5–7 days |
| Newcastle | North East England | 5–9 days |
| Sheffield | South Yorkshire | 5–9 days |
| Liverpool | Merseyside | 5–9 days |
| Belfast | Northern Ireland | 5–9 days |
| Cardiff | Wales | 5–9 days |
| Nottingham | East Midlands | 5–9 days |
| Plymouth | Devon | 5–9 days |